GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

GW Pharmaceuticals plc. (GWPH) CEO Justin Gover on Q2 2020 Results - Earnings Call Transcript

GW Pharmaceuticals Drops After Hours Despite 72% Growth of Marijuana-Derived Epidiolex

Shares of GW Pharmaceuticals (NASDAQ:GWPH) increased 13.41% in after-market trading after the company reported Q3 results.

GW Pharmaceuticals: Q3 Earnings Insights

- Total revenue increased 68 percent to $121.3 million -   - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month -  - Conference call today at 4:30 p.m. EDT –

GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress

AstraZeneca

Vertex Pharmaceuticals

Some of the most promising stocks on the market right now are pharmaceuticals.

3 Pharmaceutical Stocks That Can Make You Rich

Arena Pharmaceuticals

Amplify Seymour Cannabis ETF

GrowGeneration Corp

Innovative Industrial Properties

Amplify Alternative Harvest ETF

Global X Cannabis ETF

Scotts Miracle-Gro

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Zynerba Pharmaceuticals

Pharma Medical Cannabis More Robust And Resilient (Podcast)

The FDA approved a new indication for the company’s top-selling product.

Why GW Pharmaceuticals Stock Is Up Today

The company's star CBD drug can now be prescribed for a new condition, and its age range for a previous approval has been expanded.

GW Pharmaceuticals' Epidiolex Wins New FDA Approvals

Shares of GW Pharmaceuticals GWPH, +4.45% rallied 5.0% in trading on Monday after the drugmaker said its cannabinoid drug Epidiolex had received approval from the Food and Drug Administration for a new indication.

GW Pharma's stock rallies after its cannabinoid drug gets a new FDA approval

GW Pharmaceuticals PLC (NASDAQ: GWPH) shares popped early on Monday morning after the company announced that it received a key approval from the U.S.

How GW Pharma Is Expanding Its Cannabidiol Seizure Treatment

– Age-range for all EPIDIOLEX indications expanded to include patients  one year of age and older –

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

Wall Street analysts think this stock could double. Are they right?

Should Investors Buy GW Pharma Stock Right Now?

Amyris

Village Farms International

These are the marijuana stocks on the nasdaq stocks with the best value, fastest growth, and best performance for August.

Top Marijuana Stocks on the NASDAQ for August 2020

Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.

Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

Trulieve Cannabis Corp.

These are some of the safer buys in the industry.

2 Top Pot Stocks to Buy in a Recession

BioMarin Pharmaceutical

Galapagos

Binary events could send shares of these stocks screaming higher, or lower, soon.

3 Biotech Stocks With Big Incoming Catalysts

LONDON and CARLSBAD, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6th, 2020 its financial results and operational progress for the second quarter ending June 30th, 2020. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release and on the Company website (www.gwpharm.com) in the investor section. A replay of the call will also be available through the Company's website shortly after the call.

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020

Corbus Pharmaceuticals Holdings

What’s the choice between these U.K and U.S. biotech-cannabis companies?

Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals

GW Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.
The post GW Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

GW Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark

Shares of GW Pharmaceuticals PLC gwph fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the cannabis-derived epilepsy drug Epidiolex, citing disappointing physician feedback regarding "off-label" use of the drug.

GW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish view

Here's why a small investment in GW Pharmaceuticals can go a long way.

Could GW Pharmaceuticals Be a Millionaire-Maker Stock?

New Reasons For GW Pharmaceuticals To Ride High

Three cannabis stocks have a shot at the psychological $1 billion sales mark in either 2021 or 2022.

The First Pot Stock to Hit $1 Billion in Annual Sales Will Be.

Aurora Cannabis

Aphria

Canopy Growth

Cronos Group

Curaleaf Holdings, Inc.

HEXO Corp

Tilray Brands

As the coronavirus breakout was just beginning to be seen as a major threat to our health and to the economy back in March, it wasn’t clear what the implications might be to the cannabis industry, which was already struggling with a capital crunch that had intensified during the vaping crisis in.

Three Reasons To Be Bullish On Cannabis Stocks

Here's how the leading cannabinoid-focused biotech stacks up against the top cannabis-focused REIT.

News for GW Pharmaceuticals Stock (GWPH)